Agios Pharmaceuticals (AGIO) Change in Account Payables (2012 - 2026)

Agios Pharmaceuticals' Change in Account Payables history runs 15 years deep, the most recent figure standing at -$5.0 million for Q1 2026.

• Quarterly Change in Account Payables fell 76.99% year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$426000.0 (down 118.13% YoY) and the FY2025 annual result came in at $1.7 million, down 73.55% from the prior year.
• Change in Account Payables was -$5.0 million for Q1 2026 at Agios Pharmaceuticals, down from -$1.1 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $8.1 million in Q4 2022 and bottomed at -$9.8 million in Q1 2023.
• A 5-year average of -$114294.1 and a median of -$756000.0 in 2024 frame the typical range for Change in Account Payables.
• Peak annual rise in Change in Account Payables reached 436.06% in 2025, while the deepest fall reached 297.27% in 2025.
• Agios Pharmaceuticals' Change in Account Payables stood at $8.1 million in 2022, then slumped by 143.8% to -$3.5 million in 2023, then surged by 78.6% to -$756000.0 in 2024, then slumped by 51.46% to -$1.1 million in 2025, then plunged by 336.07% to -$5.0 million in 2026.
• Business Quant data shows AGIO's Change in Account Payables at -$5.0 million in Q1 2026, -$1.1 million in Q4 2025, and $1.8 million in Q3 2025.